Antibacterial agent 338
Antibacterial agent 338 (Compound 65) is an antibacterial agent and GyrB inhibitor, with an IC50 of 12.60 nM against GyrB from E. coli. Antibacterial agent 338 binds to the ATP-binding domain of E. coli GyrB, thereby inhibiting the ATPase activity of GyrB. Antibacterial agent 338 exhibits broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria. Antibacterial agent 338 reduces bacterial load in a neutropenic mouse thigh infection model. Antibacterial agent 338 can be used for the research of Acinetobacter baumannii infection.
For research use only. We do not sell to patients.
- Formula: C25H28FN9O
- Molecular Weight:489.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
Antibacterial agent 338 (0.038-10000 nM; 60 min) potently inhibits the ATPase activity of E. coli DNA GyrB, with an IC50 value of 12.60 nM[1].
Antibacterial agent 338 (0.03-64 μg/mL; 18-20 h) exhibits broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria, with a MIC of 0.5 μg/mL against the multidrug-resistant *Acinetobacter baumannii* strain Aba-2024-D2-018[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (half male and half female, 18-22 g, neutropenic via cyclophosphamide injection)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 20 mg/kg (two doses 6 hours apart)
-
Administration:i.v.; single dose; two doses 6 hours apart
-
Result:Achieved a bacterial burden reduction comparable to positive controls (levofloxacin and compound 9) at 20 mg/kg.
Produced a 2.65-log10 CFU/g reduction in bacterial burden.
Produced a 4.57-log10 CFU/g reduction, corresponding to >99.99% bacterial eradication, with bacterial burden reduced to pretreatment levels.
Chemical Information
-
Molecular Weight 489.55
-
Formula C25H28FN9O
-
SMILES
C/C([C@H](N)C)=C(C1)/CN1C2=NC(OC3=CN=C(NC4CC4)N=C3)=NC5=C2C6=CC(F)=CC(NC)=C6N5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Antibacterial agent 338
- Antibacterial agent338
- Antibacterial agent-338
- Bacterial
- DNA/RNA Synthesis
- E. coli GyrB
- GyrB ATPase activity
- neutropenic murine thigh infection model
- hERG K+ channel
- CHO-hERG cells
- Acinetobacter baumannii
- DNA gyrase B
- multidrug-resistant acinetobacter baumannii infection
- multidrug-resistant Gram-negative bacteria
- ATP-binding domain
- Inhibitor
- inhibitor
- inhibit